DICE study
Key Information
Chief Investigator: Dr Jonathan Krell
ICTU collaboration: Operations; Statistics;Database
Email: dice-trial@imperial.ac.uk
Study website: Clinical trials
Trial registration: EudraCT Number: 2016-000065-23
Clinical Trial. Gov: NCT03648489
Status: Follow-up
DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma)
An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma)